OBJETIVO: Analisar o desempenho do Programa Farmácia Popular do Brasil perante os setores público e privado, em relação a: disponibilidade, preço e custo, para o paciente, de medicamentos para hipertensão e diabetes.
Cláudia Du Bocage Santos Pinto +4 more
doaj
[Difficulties encountered during the pandemic reported by dentists]. [PDF]
Brítez Distéfano S +3 more
europepmc +1 more source
[Impact of an integrated and centralized drug policy: the case of the province of Buenos Aires, ArgentinaImpacto de uma política de medicamentos integrada e centralizada: o caso da província de Buenos Aires, Argentina]. [PDF]
Marín GH +7 more
europepmc +1 more source
[Rh blood group: Review and importance of genotyping]. [PDF]
Campos-Aguirre E +3 more
europepmc +1 more source
[Approach to digital transformation in healthcare to reduce the digital divide]. [PDF]
Vidal-Alaball J +5 more
europepmc +1 more source
[Evaluating the Effectiveness of Smoking Cessation Treatment Funding in Public Health Systems]. [PDF]
Camarelles Guillem F +2 more
europepmc +1 more source
[Therapeutic positioning reports: Experience in Spain during the period 2013-2019]. [PDF]
García V +4 more
europepmc +1 more source
[High-cost medicines: the difficult balance between individual and collective rightsMedicamentos de alto custo: o difícil equilíbrio entre direitos individuais e coletivos]. [PDF]
Marin GH.
europepmc +1 more source
[Twenty years since the publication of medication price regulation in Brazil: time to update?] [PDF]
Melo VA, Santana RS, Galato D.
europepmc +1 more source
[Insulin: prices, availability, and affordability in public and private Peruvian pharmaciesPreço, disponibilidade e acessibilidade à insulina em farmácias públicas e privadas no Peru]. [PDF]
Tenorio-Mucha J +4 more
europepmc +1 more source

